The US Food and Drug Administration declined to approve the drug for people with type 1 diabetes and chronic kidney disease.

Eli Lilly and Novo Nordisk are likely to introduce its popular injectable drugs semaglutide and tirzepatide in India in 2025.

When you’re in your 30s, married to the love of your life with four beautiful children, the last thing you think you’ll hear ...

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...